BiotechTube

Quizartinib + Placebo + Chemotherapy

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leukemia

Conditions

Leukemia

Trial Timeline

Nov 19, 2024 → Jun 26, 2030

NCT ID
NCT06578247

About Quizartinib + Placebo + Chemotherapy

Quizartinib + Placebo + Chemotherapy is a phase 3 stage product being developed by Daiichi Sankyo for Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06578247. Target conditions include Leukemia.

What happened to similar drugs?

20 of 20 similar drugs in Leukemia were approved

Approved (20) Terminated (1) Active (0)
✅micafungin + posaconazoleAstellas PharmaApproved
✅PirtobrutinibEli LillyApproved
✅PirtobrutinibEli LillyApproved
✅Pirtobrutinib + IdelalisibEli LillyApproved
✅Ibrutinib 420 mg + Ibrutinib 560 mgJohnson & JohnsonApproved
✅Venetoclax + AzacitidineAbbVieApproved
✅Venetoclax + Azacitidine + AzacitidineAbbVieApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06578247Phase 3Recruiting

Competing Products

20 competing products in Leukemia

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
11
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
42
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
PRGN-3006 T CellsPrecigenPhase 1
27
BisantreneRace OncologyPhase 2
29
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
15
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
25
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
ZN-d5Zentalis PharmaceuticalsPhase 1
19
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
26
Pirtobrutinib + IbrutinibEli LillyPhase 3
47
LY2523355Eli LillyPhase 1
21
TomivosertibeFFECTOR TherapeuticsPhase 1
23
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
40